The National Institute of Health (NIH) is bringing together more than a dozen leading biopharmaceutical companies and US Federal and International agencies to develop a strategy for a coordinated research response to the COVID-19 pandemic. The planned partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes, and leveraging assets among all partners to rapidly response to the COVID-19 and future pandemics. A full power of biomedical research enterprise is needed to come together to swiftly advance the most promising vaccine and therapeutic candidates that can help end of the COVID-19 global pandemic. The four fast-track focus areas, each led by highly motivated working group of senior scientists, are: standardize and share preclinical evaluation methods, prioritize and accelerate clinical evaluation of therapeutic candidates, maximize clinical trial capacity & effectiveness, and advance vaccine development.
https://www.sumeetsud.com/nih-to-speed-covid-19-vaccine-and-treatment-options/
https://www.sumeetsud.com/tag/NIH/
https://www.sumeetsud.com/tag/covid-19/
https://www.sumeetsud.com/tag/treatment/